PRCC Inhibitors
Chemical inhibitors of PRCC can act through various cellular pathways to reduce its activity. Staurosporine is a potent kinase inhibitor that hinders the phosphorylation of PRCC, directly leading to its decreased activity since PRCC function hinges on its phosphorylation status. Similarly, Bisindolylmaleimide I targets protein kinase C (PKC), a kinase that can phosphorylate PRCC, and its inhibition leads to reduced phosphorylation and subsequent activity of PRCC. LY294002 and Wortmannin, both PI3K inhibitors, also decrease PRCC activity by limiting the PI3K/Akt pathway, which is known to phosphorylate and regulate proteins like PRCC. The MEK inhibitors U0126 and PD98059 serve a similar function; they restrain the MAPK/ERK signaling cascade, which is associated with the activity of PRCC, thus leading to a decline in PRCC's functional state.
Additionally, Rapamycin, an mTOR inhibitor, suppresses the mTOR signaling pathway, which has downstream effects on PRCC, resulting in its reduced activity. SP600125, by inhibiting JNK, prevents the phosphorylation of PRCC or proteins associated with it, leading to diminished PRCC activity. SB203580 and Sorafenib both inhibit distinct kinases within the MAPK pathway (p38 MAPK and tyrosine kinases, respectively), which has repercussions on the activity of PRCC by diminishing its function within this signaling route. Y-27632's inhibition of ROCK kinase influences cytoskeletal arrangement and potentially the activity of PRCC, reducing its functional capacity. Finally, Triciribine's inhibition of Akt leads to less phosphorylation of PRCC, thereby decreasing its activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. Protein kinase inhibitors can inhibit the phosphorylation of PRCC, thereby reducing its activity, as PRCC function is dependent on phosphorylation status. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). Since PKC can phosphorylate substrates like PRCC, inhibition of PKC decreases the phosphorylation and thus the activity of PRCC. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K/Akt pathway. This pathway can be involved in the phosphorylation of proteins, including PRCC. Inhibition of PI3K/Akt pathway leads to decreased phosphorylation and activity of PRCC. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. PRCC has been shown to interact with the MAPK pathway, and inhibition of this pathway by U0126 can decrease PRCC activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is involved in cell growth and proliferation pathways that can include PRCC as a downstream effector. Inhibition of mTOR leads to reduced function of PRCC. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can phosphorylate various substrates including those interacting with PRCC. Inhibition of JNK activity results in decreased PRCC activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway can influence the activity of PRCC. Inhibition of p38 MAPK leads to reduced activity of PRCC. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which can reduce ERK pathway activity. Since PRCC interacts with the MAPK/ERK pathway, inhibition of this pathway by PD98059 results in decreased activity of PRCC. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, it can decrease the activity of downstream proteins including PRCC that may be regulated by the PI3K/Akt pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of ROCK kinase, which can influence cytoskeletal dynamics and possibly the function of PRCC. Inhibition of ROCK can result in decreased activity of PRCC. | ||||||